Sign in3 stories
The company said it intends to buy back stock at $5.00 to $5.75 per share, funded by cash on hand, with the offer expected to run late August through late September 2026.
SEC filing
The company also began collecting on its $950 million Moderna settlement and outlined a plan to return up to $230 million to shareholders, though timing remains unconfirmed.
SEC filing
The same 8-K disclosing new Pfizer/BioNTech suits and the $230M buyback also reveals a terminated RSV agreement and litigation bonuses for Arbutus executives.
SEC filing